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Introduction
Since 1988, umbilical cord blood (CB) has been successfully
used as a source of stem cells for hematopoietic reconstitution
in allogeneic hematopoietic stem cell transplantation (HSCT).
The first transplant using CB was performed in a 5-year old
boy with Fanconi anemia, an inherited bone marrow failure
syndrome which can only be cured by allogeneic HSCT.1 The
mother was pregnant with a girl who was known, before birth,
to be HLA-identical to her brother and not a carrier of the same
genetic defect. The sister’s CB was collected and cryopreserved
at birth and transplanted to the patient. More than 22 years
later, the patient is alive and well with a normal hematologic
and immunological reconstitution provided by his donor cells.  
In 1991, the first public CB bank (CBB) was established at the
New York Blood Center2 and, in 1993, the first unrelated CB
transplant (CBT) was performed in a 4-year old child with
leukemia.3 Since then, more than 100 public CBBs have collect-
ed over 500,000 CB units (CBUs) from altruistic, free and
anonymous donations that resulted in over 25,000 unrelated
CBT worldwide. Most banks cooperate through international
registries that list publicly banked CBUs in searchable databas-
es, such as Bone Marrow Donors Worldwide (BMDW), the
Netcord Foundation, the National Marrow Donor Program
(NMDP) and other national registries, in order to provide
access to all patients in need.  International accrediting bodies
and governmental regulatory requirements are in place to
assure that publicly available CBs meet strict rules for quality
standards.4,5 Outcome data are routinely collected and are avail-
able for analysis through international data registries that allow
good monitoring and analysis of CBT activity and outcomes.
The activity of these international registries, such as Eurocord
(Figure 1) and the Center for International Blood and Marrow
Transplant Research (CIBMTR) widens our knowledge of the
use of unrelated CBT.
In contrast with the well developed public banking systems,
few countries have a centralized program for family-directed
CB collection and storage which requires different procedures
in order to obtain high-quality products. This approach is clin-
ically indicated and validated in families where the mother is
pregnant and has an existing child or has a known risk of hav-
ing a child affected by a disease which can be cured by allo-
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Umbilical cord blood transplantation from HLA-identical sib-
lings provides good results in children. These results support
targeted efforts to bank family cord blood units that can be
used for a sibling diagnosed with a disease which can be cured
by allogeneic hematopoietic stem cell transplantation or for
research that investigates the use of allogeneic or autologous
cord blood cells.  Over 500 patients transplanted with related
cord blood units have been reported to the Eurocord registry
with a 4-year overall survival of 91% for patients with non-
malignant diseases and 56% for patients with malignant dis-
eases. Main hematologic indications in children are leukemia,
hemoglobinopathies or inherited hematologic, immunological
or metabolic disorders. However, family-directed cord blood
banking is not widely promoted; many cord blood units used
in sibling transplantation have been obtained from private
banks that do not meet the necessary criteria required to store
these units. Marketing by private banks who predominantly
store autologous cord blood units has created public confu-
sion. There are very few current validated indications for
autologous storage but some new indications might appear in
the future. Little effort is devoted to provide unbiased informa-
tion and to educate the public as to the distinction between
the different types of banking, economic models and stan-
dards involved in such programs. In order to provide a better
service for families in need, directed-family cord blood bank-
ing activities should be encouraged and closely monitored
with common standards, and better information on current
and future indications should be made available. 
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ABSTRACT
geneic HSCT.1,6-9 While in public banking most pregnant
woman would be qualified to donate, family-directed
banking requires a more focused approach to identify the
few candidates that would benefit from collection. As a
result, the practice of collecting CBUs from family members
specifically stored for the potential benefit of another family
member with a disease which can be cured by HSCT is not
widespread. This is in spite of the fact that family-directed
CBT has several advantages over unrelated CBT, including
greater likelihood of survival, decreased graft-versus-host
disease (GVHD) and the opportunity to re-collect bone
marrow cells from the same donor in case of relapse or
rejection.8,9 Today, CB banking for family use is mostly an
indirect result of autologous banking, marketed by the pri-
vate sector, to families for private CB collection and storage
without any current therapeutic purpose and for potential
use by the donor later in life. A CB banked in this manner
may occasionally benefit a sibling. Whereas family-directed
banking for allogeneic purposes does not raise ethical con-
cerns, autologous CB banking in an a priori healthy family is
controversial because its value is not entirely supported by
clinical evidence. Despite this, autologous CB banking has
developed into a private industry predominantly used by
economically advantaged families.10,11 Discussion about the
development of hybrid CBB models that could combine
efforts to support all banking activities is the subject of
intense controversy because of ethical, scientific, regulatory,
economic and social concerns.12,13
The current situation of family-directed CB 
transplantation and banking
The Eurocord registry has identified 596 patients trans-
planted with related CB from 1988 to 2010 but, in contrast
to unrelated CBT, the number of related CBTs has not
increased year after year. Most recipients were children,
and all but 29 were HLA-matched. The major characteris-
tics of the patients and transplants are listed in Tables 1 and
2. Four year overall survival was 91% for patients with non-
malignant diseases and 56% for patients with malignant
diseases (Table 3 and Figure 2). The cumulative incidence
(CI) of neutrophil engraftment was 91±3% in a median of
22 days (range 12-80 days). The incidence of acute and
chronic GVHD at day 100 and at four years was 12±3%
and 13±2%, respectively (E Gluckman for Eurocord, unpub-
lished data, 2010). In another Eurocord study, on long-term
outcomes of 147 HLA-identical sibling CBT recipients with
hematologic malignancies, the 5-year disease-free survival
was 44%.14 Compared with HLA-identical BMT, HLA-
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Table 1. Disease and transplant characteristics of patients treated with
family CB transplants (n=596) (E. Gluckman for Eurocord, unpub-
lished data, 2010).
Characteristics                              Median or N           Min – Max or %
Male gender                                                  331                                  56%
Age, in years                                                    6                                    1-50
Weight, in kg                                                  19                                   3-86
Previous transplant                                      34                                    6%
Malignant diseases                                     255                                     
Acute leukemia                                            187                                31.5%
ALL                                                               140                                     
AML                                                               47                                      
Myelodysplastic syndrome                         26                                  4.5%
Chronic myeloid leukemia                         21                                  3.5%
Lymphoproliferative disorders                 11                                    2%
Non-Hodgkin’s lymphoma                       9                                       
Hodgkin’s lymphoma                                2                                       
Solid tumor                                                    10                                    2%
Non-malignant diseases                            341                                     
Aplastic anemia                                             92                                 15.5%
Fanconi anemia                                       36                                      
Hemoglobinopathies                                  193                                32.5%
Thalassemia                                              145                                     
Sickle cell disease                                     48                                      
SCID                                                                 36                                    6%
Metabolic diseases                                      15                                  2.5%
Other                                                                5                                   1.5%
Type of transplant 
Single CB unit                                               474                                79.5%
Single CB unit + bone marrow                110                                18.5%
(same donor)
Single CB unit+ other SC source             12                                    2%
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; SCID: severe com-
bined immunodeficiency; SC: stem cells.
Figure 1. Number of related and
unrelated cord blood units provided
per year, n= 6805 (E. Gluckman for





















































identical sibling CBTs displayed delayed granulocyte and
platelet engraftment, and reduced incidence of acute and
chronic GVHD, but survival was similar.15 Although the
mechanism of such GVHD reduction is not fully under-
stood, the immunological immaturity of the newborn and
the enrichment of CB in T-reg cells may account for at least
part of it. Though generated from family-related CBTs, such
clinical data, which indicated that GVHD was reduced
when CB was used instead of bone marrow, were the basis
for advocating HLA-mismatched CBTs, and for developing
unrelated CBBs and programs for HLA-mismatched trans-
plants.16-19
A number of studies have reported on efforts to system-
atically identify, collect and store CBs for family-directed
use (Table 4). Reed et al.20 were the first to document the
value of a focused program to collect and bank family-
directed CBs from donors in families with children who
have disorders which can be cured by HSCT. Cord blood
was collected in remote sites with a kit provided by the
bank. Participation was voluntary and unremunerated; 540
families from 42 different states were enrolled. Despite the
lack of experience and the heterogeneity of collection cen-
ters, the median number of cells was satisfactory, with
more than 93% of the banked CBs containing enough cells
for transplanting the sibling. Seventeen units (3.4%) had
been transplanted. The same group published data on sib-
ling donor cord blood transplantation in patients with tha-
lassemia major. Thirty-two of 96 donor-recipient pairs were
HLA identical and 14 (44%) received a CBT. Eleven of the
14 survived free of thalassemia after transplantation.24
Smythe et al.21 have reported the 10-year experience of
family-directed CB banking in the National Blood Service in
England. Informed consent, CB testing, processing and stor-
age followed the same procedures as for unrelated public
CB banking. A total of 268 CBs were collected from 244
mothers. Diagnoses were hematologic malignancies in 114
cases, non-malignant hematologic disorders in 68 cases,
immunodeficiency in 44 cases, and enzyme deficiency in 9
cases. Of the matched units, 13 were transplanted. In a
study limited to children with malignant diseases, in
Greece, Goussetis et al. have reported a low usage rate of
banked sibling CB (n=48).22 CBs were successfully collected,
but only one out of 4 children who needed HSCT was suc-
cessfully transplanted. The same authors reported their
experience in 50 families with beta-thalassemia major.23
Eight out of 12 HLA matched collections were released for
CBT. All patients survived, 7 out of 8 thalassemia free. The
authors conclude that the development of directed CBB
programs requires a policy to limit long-term storage for
E. Gluckman et al.
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Table 3. Outcomes after family CB transplant (n=519) (E. Gluckman
for Eurocord, unpublished data, 2010).
Outcomes N or %
Follow up in months, median (range) 48 (3-248)
Neutrophil recovery 477/519
Time in days, median (range) 22 (12-80)
Cumulative Incidence at day 60 (%) 91±2%
Acute GvHD 71/519
Grade 0-1 448 (86%)
Grade II 52 (10%)
Grade III 15 (3%)
Grade IV 4 (1%)




Cumulative incidence at 4 years (%) 13±2%
Overall survival at 4 years (%) 75±2%
Malignant diseases 56±4%, n=188/218
Non-malignant diseases 91±2%, n=259/301
Non-relapse mortality at 4 years (%) 8±2%




Figure 2. Overall survival at 4-years after related CB transplants
(n=519) according to disease category (E. Gluckman for Eurocord,
unpublished data, 2010).
Table 2. Donor and transplant characteristics of patients treated with
family CB transplants (E. Gluckman for Eurocord, unpublished data,
2010).
Characteristics Median or N Min-Max or %
Storage time of the CB unit, in months 7 0-162
Total nucleated cells at infusion (107/kg) 3.9 1-20
Total CD34+ at infusion (105/kg) 1.5 1-30
ABO compatibility
compatible 262 66%
minor incompatibility 50 13%
major incompatibility 83 21%
Sex-matched (CB/patient) 292 51%
Conditioning regimen
reduced intensity 59 12%
myeloablative 422 88%
with TBI 132
with busulfan (or treosulfan) 290
Use of anti-thymocyte globulin 175 38%
GVHD prophylaxis
none 8 2%
CsA alone 275 55%
CsA + steroids 62 12%
CsA + MTX ± steroids 111 22%
Other 45 9%
TBI: total body irradiation, CsA: cyclosporine A, MTX: methotrexate.
Non-malignant (n=301): 91±2%
Malignant (n=218): 56±4%

















banked CBs with a low probability of usage. For example,
CBs that are not HLA-matched to the patient or that are
HLA-matched to a patient who has achieved long-term
remission are unlikely to be used, while banking for hemo-
globinopathies increases the probability of usage to 16%. In
Italy, the family-directed cord blood banking is supported
by a national program (Ministerial Decree of 18 November
2009). The Centro Nazionale Sangue (CNS) reported 2,176
CB units banked (242 were banked in the year 2010) by the
Italian public bank network up to 31 December 2010. Of
these, 129 were used for transplantation. In France, two
CBBs (Hospitals Saint-Louis in Paris and Henri Mondor in
Creteil) have collected 548 family-directed CBUs (E.
Gluckman for Eurocord, unpublished data, 2010). The first
banked all CBUs as requested by the patients’ physicians
(number collected for 437 patients: 216 leukemia, 118
hemoglobinopathies, 23 aplastic anemia, 17 immune defi-
ciencies, 10 Fanconi anemia, 6 metabolic diseases, 5 solid
tumors and 42 with unreported diagnoses), the second
banked 111 CBUs mostly from siblings of patients with
sickle cell disease (89 collections, i.e. 80%). Twenty-four
CBTs were performed from HLA-identical sibling donors,
13 from the first bank and 11 from the second bank.
Outcome was excellent: the 5-year overall survival was
83%, and 100% when considering hemoglobinopathies
only. These data indicate that hemoglobinopathies are
extremely important indications of cases in which family-
directed disease-oriented CB banking is worthwhile. 
These studies should be contrasted with the as yet limit-
ed reports of the experience of using private banking as the
source of CB for either autologous or sibling use. Thornley
et al. have presented data from a 2004 cross-sectional survey
of 152 pediatric HSCT physicians from 57 centers in the
United States and Canada.25 The respondents reported 9
autologous and 41 allogeneic transplants using privately
banked CB. In 36 of 40 allogeneic cases, the CB had been
collected because of a known indication in the recipient.
The indications for allogeneic CBTs were acute leukemia
(20 cases), hemoglobinopathies (7 cases), Fanconi anemia (7
cases) and others (7 cases).  The 9 autologous CBTs were
performed in severe aplastic anemia (4 cases), neuroblas-
toma (one case), retinoblastoma (one case), Schwachman-
Diamond syndrome (one case), brain tumor (one case) and
one with unreported diagnosis.  Few respondents stated
they would choose autologous CB over alternative stem cell
sources for treating acute leukemia in second remission,
whereas 55% said they would choose autologous CB to
treat high-risk neuroblastoma or aplastic anemia in the
absence of an available donor. No respondent would rec-
ommend banking autologous CB for a newborn when both
parents are of northern European descent; 11% would rec-
ommend such banking when parents are of different minor-
ity ethnicities. Indeed, the probability of using family-
directed CB for allogeneic HSCT is very low when patients
have frequent, highly represented haplotypes in the large
unrelated bone marrow or CB inventories, whereas the sit-
uation is quite different in families with parents of different
ethnic minorities and for whom the chance of finding a suit-
able unrelated donor is limited. However, current results of
HLA matched sibling CBT are better than when an unrelat-
ed bone marrow or CB donor is used. More recently,
Rosenthal et al. have reported the successful use of banked
autologous CB to treat severe aplastic anemia in 3 patients.26
However, they note that the probability of being able to use
an autologous CB is very low (4 in a million). 
Cost-benefit analysis
The potential cost of family-directed banking can be esti-
mated by looking at matched rates found in the published
studies and estimating the average cost of CBUs banked
using the data published by the Institute of Medicine (IOM)
in 2004, where the costs of collecting, processing and bank-
ing for public banking are estimated. There, these costs
were estimated to be approximately $1,500 per unit plus
$50 annually for storage. The IOM estimates reflect costs of
collecting but not of processing units determined to be
unsuitable for collection prior to any processing or the costs
of HLA typing for all banked units. Family-directed banking
would likely incur lower per-unit banking costs as units of
smaller size would be acceptable for banking and HLA test-
ing would only be carried out at the time of potential need.
The estimated costs per unit used are consistent with graft
acquisition costs for unrelated donors when costs of donor
screening, testing and selection are taken into account. 
According to the 2011 study by Rosenthal et al.,26 the cost
for the first year of private storage, including collection,
shipping and storage fees, varies in the United States from
$1,993 to $2,195 plus an annual storage fee of $125. Of
more than 355,000 CBUs stored in two large private banks,
77 were used for allogeneic HSCT and 32 for autologous
HSCT. The average cost of the CBU used would then be
over 100 times that of an unrelated bone marrow or CB
product. 
Kaimal et al.27 have investigated the cost-effectiveness of
private CB banking relative to no banking. They conclude
that private banking is not cost-effective because it costs an
additional $1,374,246 per life-year gained. In sensitivity
analysis, if the cost of CB banking is less than $262 or the
likelihood of a child needing a HSCT is greater than 1 in
110, private banking becomes cost-effective. They con-
clude, therefore, that private CB banking is cost-effective
only in families with children with a very high likelihood of
needing a HSCT. 
Indications of family-directed CB banking is now limited
Table 4. Number of family directed cord blood units stored and transplanted.
Ref                                      Units   Units    Diagnosis
                                           banked   used
Reed20                                            540          17        Data not reported
Smythe21                                       268          13        Thalassemia, n=7
                                                                                    Acute lymphoblastic leukemia, n=3
                                                                                    Bone marrow failure syndromes, n=3
Goussetis22                                    48            1         Acute leukemia, n=1
Goussetis23                                    50            8         Thalassemia, n=8
Italy (CNS data)                        2176       129       Data not reported
(E. Gluckman for Eurocord, 
unpublished data, 2010).
France (E. Gluckman                437          13        Acute leukemia, n=4
for Eurocord,                                                          Immune deficiency, n=3
unpublished data, 2010)                                       Thalassemia, n=2
Hospital Saint Louis                                              Chronic leukemia, n=1
                                                                                    Fanconi anemia, n=1
                                                                                    Metabolic disease, n=1
                                                                                    Unknown, n=1
France (E. Gluckman                111          11        Sickle cell disease, n=9
for Eurocord,                                                         Thalassemia, n=2
unpublished data, 2010)
Hospital Henri Mondor               
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to children with hematologic malignancies, genetic disor-
ders or acquired aplastic anemia. If a genetic disease is the
indication for HSCT, the chances of a sibling being a non-
carrier and HLA match range from 1:8 to 1:16, depending
on the inheritance of the genetic condition. In some dis-
eases (e.g. hemoglobinopathies) matched carrier siblings are
appropriate donors, but in others (e.g. inherited metabolic
disorders) they cannot be utilized. In the United States, the
annual incidence of ALL in children aged 0-19 years is esti-
mated at 30.6 in a million for Caucasians and 15.9 in a mil-
lion for Afro-Americans. The annual incidence of severe
aplastic anemia is estimated at 3 in a million and that of
high-risk neuroblastoma which can be treated by autolo-
gous transplant at 3-5 in a million.25 Moreover, parents con-
sidering family banking in the absence of a patent indica-
tion should be informed of the remote likelihood that a CB
will be used for the donor child or another family member.
It should, however, be noted that these considerations are
based on current hematologic indications without taking
into account the potential use of CB in non-hematologic
diseases. Indeed, several studies are exploring the possibili-
ty of treating infants with cerebral palsy or type 1 diabetes
using autologous CBTs28 (www.clinicaltrials.gov). If current
clinical trials are successful, directed CB banking may
become more and more cost efficient as new indications
appear. 
Discussion
Efforts to expand family-directed banking also have to
take into account alternatives to sibling CBT, especially in
non-malignant settings when HSCT could be delayed, such
as the use of a sibling bone marrow.  This approach is less
expensive than a CBT and has shown good clinical results;
however, the process of graft acquisition, although safe, is
not harmless in a very young donor. Moreover, the delay of
the transplant and the potential for other complications, or
the possibility that the sibling donor may not otherwise be
fit to donate when needed, should also be considered. CB
collection is harmless for the baby and the mother and does
not raise any ethical concern,11 while one should consider
the possible side effects of bone marrow or peripheral
blood collection for mobilized hematopoietic stem cells in
young children, which to our knowledge have not yet been
evaluated.  Moreover, in some cases, the patient cannot
wait long enough for the donor's bone marrow to be safely
collected, e.g. when HSCT is indicated for leukemia, aplas-
tic anemia or a hereditary disorder, such as severe com-
bined immunodeficiency, osteopetrosis or mucopolysac-
charidosis. In all these cases, the current alternative options,
in the absence of a matched related or unrelated donor, are
to propose a haploidentical family hematopoietic stem cell
bone marrow or peripheral blood transplant or a mis-
matched unrelated cord blood transplant whose results are
clearly less favorable than an HLA matched sibling cord
blood transplant.
Family-directed CB banking may have other advantages.
For instance, CB usage may be the only practical option
available in developing countries where infant mortality is
high and the risks associated with bone marrow collection
and/or insertion of central venous access for obtaining
mobilized hematopoietic stem cells in the peripheral blood
are a concern. Where the risk of acquired infectious diseases
such as hepatitis or HIV infection is present, collection of
the CB may also be the best way to limit or prevent the risk
of transmission of infectious diseases, since testing of the
CB units for these diseases can then be carried out to assure
no transmission. However, it is important to be aware that
in this context, a transplant program would only be feasible
if the necessary basic healthcare infrastructure (e.g. vaccina-
tion, air, water quality, nutrition, etc.) and education policies
are well established to ensure quality and safety.
Hemoglobinopathies are, indeed, the main indications of
CBT in many developing countries and, even though data
on the cost of CB banking and transplantation in these
countries is unknown and could vary from country to coun-
try, one can speculate that the cost of CB HSCT might be
acceptable compared with life-long complications, iron
chelation or the cost of obtaining bone marrow. If a cost-
effective way can be found to identify a matched CB, this
could permit an extended use of this therapy in these coun-
tries. Costs might even be decreased by the development of
dedicated centers for treatment of hemoglobinopathies in
developing countries where the cost of labor is lower than
in developed countries. The use of reduced intensity condi-
tioning regimens and protocols of supportive care adapted
to the local situation might decrease the cost even further. 
Further efforts should be made to determine whether a
national high-quality program of sibling CB banking can be
maintained at relatively low cost despite the logistic diffi-
culties of organizing collections from many hospitals and
issuing CBs for transplantation to diversely located trans-
plant centers. Growing recognition of the benefits of fami-
ly-directed banking has resulted in programs to more sys-
tematically test the cost and benefit of this approach. These
include a pilot program currently underway in the United
States, sponsored by the Department of Health and Human
Services and administered through NMDP, which involves
the development of promotional materials and campaigns
to create awareness of the value of directed donation bank-
ing. Five public banks and one family bank participate
under agreements to collect, store and bank units that meet
the program criteria.  The processes applied to these CBs
are almost identical to those applied to public units.  Many
private banks also offer this service free of charge for fami-
lies in need. These should be encouraged but only if they
are pursued along with the goal of banking high quality
units.29 Most private banking is not subject to the same reg-
ulatory review that public banks are required to satisfy. For
instance, in the United States, autologous banks do not
need to be licensed. Voluntary accreditation may address
the lack of regulatory overview but many autologous banks
do not seek accreditation through Fact-Netcord, the stan-
dard for public banks that has been adopted in many
European countries, as well as in Australia and Canada.
Specific criteria for family-directed banking have been
established by Fact-Netcord but few existing private banks
are Fact-accredited. Accreditation is also available through
the American Association of Blood Banks (AABB) or other
national accreditation bodies. 
In order to find a compromise, public-private hybrid bank
models are currently the subject of intense discussion.10-13
One driver for these models is to improve the financial via-
bility of the CBBs. A number of models for combined bank-
ing have been developed, including joint marketing of sep-
arate banking operations, opportunities to split units for pri-
vate and public use, and the offer to initially bank units as
either public or private, but with the potential of converting
their status at a later date or event. To be useful to families,
E. Gluckman et al.
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these new approaches will need to be more rigorously
adopted, accreditation standards need to be applied, the
accuracy of their informed consent improved, benefits to
help research on CB cells need to be shared, and sibling
banking when there is a clear indication for allogeneic
HSCT need to be offered. In order to transfer some private
units to the public inventory, a WMDA policy statement on
the combined private and public banking of CB and other
related products has been established
(www.worldmarrow.org). Many families with children affect-
ed by hematologic malignant disease or a hereditary disor-
der later have other children. However, births are scattered
among hospitals that may lack the infrastructure required to
collect or bank locally and CB may often be collected in
hospitals that are not accredited for collection, unlike CB
collected by accredited maternity units.26 Efforts to improve
the quality of collections will, therefore, be an important
part of any program to collect family-directed units.
Optimal policies, procedures and indications have not been
clearly established for use in these routine birthing centers.
Information should state clearly that banking CB does not
guarantee that the cells will provide a cure or be applicable
in every situation.29 Medical treatments using family
banked cord tissue are still in an early phase of research and
are not currently available, and there is no guarantee that
therapies will be developed in the future. Gene and cellular
therapies for various disorders, including thalassemia or
severe combined immunodeficiency syndrome, show
promising results.30,31 In the future, prenatal diagnosis may
identify patients who may benefit from gene therapy using
their own CB. In this case, gene-modified CB cells could be
infused early in life avoiding the treatments and complica-
tions related to these diseases. Pre-implantation genetic
testing has been approved in many countries to ensure that
a pregnancy will result in a child free from a serious inher-
ited disorder and, HLA-identical to his sibling, a candidate
for an allogeneic HSCT. This practice will increase the prob-
ability of finding an HLA-identical sibling donor and so the
number of sibling CB collections is likely to increase.32 The
potential scope of medically indicated family-directed CB
banking is considerable (Table 5). Another important factor
using family-directed CBU is that the unit could be com-
bined with different sources of stem cell, such as BM from
the same donor, in case it is needed. So far there have been
over 100 transplants reported to Eurocord, using related CB
in combination with BM for malignant and non-malignant
diseases. In the future, some non-hematologic diseases
might be treated with allogeneic or autologous cells.33
Continuing academic research and help from the industry
for the development of new products and for the imple-
mentation of worldwide regulation will control and guaran-
tee the quality, safety and potency of the CB market on the
basis of new scientific and clinical protocols and rigorous
clinical trials. 
Conclusion
The use of CB units for allogeneic HSCT has saved many
lives all over the world and holds great promise to benefit
many more. The current practice and approach to CBB,
both public and private, are overlooking an important
opportunity to provide an optimal cell source for families in
whom there is the possibility of collecting CB for a sibling
with a known condition that would benefit from a related
CBT. For this purpose private banks should meet the same
standards, quality control and accreditation requirements as
those required for public cord blood banking. Outcomes
can be improved and more lives saved through a more
organized approach to the identification and collection of
CB for family-directed uses.
Appendix
EBMT centers who kindly provided data on related cord
blood transplant (in alphabetical order):
Algeria - Alger: Centre Pierre et Marie Curie/Australia -
Sydney: The Children’s Hospital at Westmead &
Randwick/Austria – Graz: Medical University Graz/Innsbruck:
University Hospital Innsbruck/Vienna: St. Anna
Kinderspital/Belarus - Minsk: Belorussian Centre for Paediatric,
Oncology and Hematology/Belgium - Brussels: Cliniques
Universitaires St. Luc, Institut Jules Bordet, Children`s University
Hospital, BMT Unit/Gent: University Hospital Gent/Haine-St-
Paul: Hôpital de Jolimont/Leuven: University Hospital Leuven
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Table 5. Indication of family-directed cord blood use in developed countries
Indication Validated Investigational
Diseases Hematologic: • Non-hematologic 
- Acute leukemia - Cerebral palsy
- Lymphoma - Diabetes
- MDS/MPD - Hearing loss
- Inherited and acquired bone marrow failure syndrome • Immunotherapy for infectious disease or against tumors




Source Cord blood Cord blood
Umbilical cord 
Placenta




Quality and safety Supposed good quality if in experienced local hospitals Unknown 
MDS/MPD: myelodysplastic syndrome; myeloproliferative disorders; HSC: hematopoietic stem cells; MSC: mesenchymal stromal cells; IPS: induced pluripotent stem cell.
(Dept. of Paediatrics), University Hospital Gasthuisberg (Dept. of
Hematology)/Yvoir: UCL Mont-Godinne/Brazil - Campinas:
Univ. Est. de Campinas/Bulgaria - Sofia: Children`s Onco-
Hematology Hospital/Croatia - Zagreb: University Hospital
Center Rebro/Czech Republic - Prague: University Hospital
Motol/Denmark - Copenhagen: Rigshospitalet/Finland - Helsinki:
University of Helsinki, Hospital for Children &
Adolescents/France – Angers: Centre Hospitalier Régional
d’Angers/Besançon: Hôpital Saint Jacques/Bordeaux: Hôpital
Haut-Lévêque, CHU Bordeaux Groupe Hospitalier Pellegrin-
Enfants/Clermont-Ferrand: Hôtel Dieu CHU/Jean Perrin/Créteil:
Hôpital Henri Mondor/Grenoble: Tronche CHU-Albert
Michallon/Lille: Claude Huriez/Lyon – Hôpital Debrousse (pédi-
atrie)/Marseille: Hôpital d'Enfants de La Timone/Nancy: Hôpital
de Brabois/Nantes: Hôtel Dieu/Nice: Hôpital de l’Archet/Paris:
Hôpital Necker (adulte), Hôpital Necker Enfants Malades,
Hôpital Saint-Louis, Hôpital Robert Debré/Poitiers: Hôpital Jean
Bernard/Rennes: Hôpital de Pontchaillou/Rouen: Hôpital Charles
Nicolle (pédiatrie)/Saint-Etienne: Hôpital Nord Institut de
Cancérologie de la Loire/Strasbourg: Hôpital de Hautepierre (pédi-
atrie)/Germany - Berlin: Charité-CVK, University Medicine
Berlin/Dresden: Universitaetsklinikum Dresden/Düsseldorf:
Universitaetsklinikum/Essen: University Hospital, Dept. of
Pediatric Hematol./Oncol/Hannover: Hannover Medical
School/Heidelberg: University of Heidelberg/Jena: University of
Jena/Munich: Klinikum Grosshadern/Tübingen: Universität
Tübingen, Medizinische Klinik/Ulm: Universitaet Ulm/Greece -
Athens: St. Sophia` Children`s Hospital/Patras: Patras University
Medical School/Hungary - Budapest: St. László Hospital, St.
István/Miskolc: Postgraduate Medical School/India - Chennai:
Apollo Speciality Hospital/Iran - Teheran: Shariati
Hospital/Ireland - Dublin: Our Lady`s Hospital for Sick
Children/Israel - Haifa: Rambam Medical Center/Jerusalem:
Hadassah University Hospital/Petach-Tikva: Schneider
Children`s Medical Center of Israel/Tel-Hashomer: Edmond &
Lily Safra Children`s Hospital, Chaim Sheba Medical
Center/Italy - Bologna: Azienda Ospedaliero-Universitaria di
Bologna/Brescia: Universitá degli Studi di Brescia/Genova:
Ospedale San Martino, Department of Haematology II, Institute
G. Gaslini,/Milano: San Raffaele Scientific Institute/Monza:
Ospedale San Gerardo, Clinica Pediatrica dell`Universita di
Milano Bicocca/Padova: Clinica di Oncoematologia
Pediatrica/Pavia: Fondazione IRCCS Policlinico San
Matteo/Pescara: Ospedale Civile Department of
Hematology/Pisa: Azienda Ospedaliera Universitaria
Pisa/Reggio_Calabria: Azienda Ospedaliera/Roma: Univ. ‘La
Sapienza’, Ospedale S. Camillo, Rome Transplant
Network/Torino: Ospedale Infantile Regina Margherita, Onco-
Ematologia Pediatrica, Istituto per la Ricerca e la Cura del Cancro,
Ospedale San Luigi Orbassano, University of Turin/Trieste:
Istituto per l’Infanzia Burlo Garofolo/Jordan - Amman: King
Hussein Cancer Centre/Poland – Bydgoszcz: University Hospital,
Collegium Medicum/Poznan: Poznan University of Medical
Sciences/Wroclaw: Wroclaw DCTK, Wroclaw Medical
University/Portugal – Lisboa: Inst. Portugues Oncologia/Porto:
Inst. Portugues de Oncologia do Porto/Russia - Moscow: Russian’s
Children`s Hospital/St. Petersburg: Saint Petersburg State
Medical Pavlov University/Saudi Arabia - Riyadh: King Faisal
Specialist Hospital & Research Centre/Spain – Barcelona:
Hospital Vall d`Hebron, Hospital Santa Creu i Sant
Pau/Córdoba: Hosp. Reina Sofia/Madrid: Hospital Gregorio
Marañón, Hospital Universitario La Paz, Niño Jesus Children`s
Hospital, Hospital Universitario Puerta de Hierro/Málaga:
Hospital Carlos Haya/Palma_De_Mallorca: Hospital
Universitari Son Dureta/Sevilla: Hospital Universitario Virgen del
Rocío/Valencia: Hospital Infantil La Fe/Slovakia - Bratislava:
Pediatric University Teaching Hospital/South Africa -
Cape_Town: University of Cape Town Faculty of Health
Sciences/Sweden - Goeteborg: Sahlgrenska University Hospital,
The Queen Silvia Children’s Hospital/Lund, University
Hospital/Stockholm: Huddinge University Hospital, Karolinska
University Hospital Children’s Hospital/Umeå: Umea University
Hospital/Uppsala: University Hospital/Switzerland, Zürich,
University Children’s Hospital/The Netherlands - Leiden:
University Hospital/Nijmegen: Radboud University - Nijmegen
Medical Centre/Utrecht: University Medical Centre, University
Hospital for Children/Turkey - Ankara: Hacettepe University
Children's Hospital, Ankara University Faculty of
Medicine/Ankara (Cebeci): University of Ankara/Ankara Sihhiye:
Hacettepe University/Antalya: Akdeniz University Medical
School/Izmir, Ege University/United Kingdom – Birmingham:
Birmingham Children`s Hospital/Bristol: Avon Haematology Unit
Bristol Oncology Centre, Bristol Royal Hospital for
Children/Glasgow: Royal Hospital for Sick Children/Leeds: Mid
Yorkshire Hospitals NHS Trust - Yorkshire Blood & Marrow
Transplant Programme/London: St. Mary's Hospital Division of
Paediatrics, Great Ormond Street Hospital, Royal Marsden
Hospital, Imperial College Hammersmith Hospital/Manchester:
Department of Paediatric Haematology/Newcastle-Upon-Tyne:
Newcastle General Hospital (Dept. of Paediatric Immunology),
Royal Victoria Infirmary (Hematology, Paediatric Oncology
Unit)/Sheffield: Royal Hallamshire Hospital.
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